Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.

British journal of haematology - 1 Nov 2017

Hagner Patrick R, Chiu Hsiling, Ortiz Maria, Apollonio Benedetta, Wang Maria, Couto Suzana, Waldman Michelle F, Flynt Erin, Ramsay Alan G, Trotter Matthew, Gandhi Anita K, Chopra Rajesh, Thakurta Anjan

Abstract excerpt

Lenalidomide is an immunomodulatory agent that has demonstrated clinical benefit for patients with relapsed or refractory mantle cell lymphoma (MCL); however, despite this observed clinical activity, the mechanism of action (MOA) of lenalidomide has not been characterized in this setting. We investigated the MOA of lenalidomide in clinical samples from patients enrolled in the CC-5013-MCL-002 trial (NCT00875667)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytotoxicity, Immunologic
Share to Immunologic Factors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lenalidomide

Share to Lymphocyte Count

Share to Lymphoma, Mantle-Cell

Share to Peptide Hydrolases

Share to Piperidines

Share to Thalidomide

Source

Identifiers

PMID: 28771673
DOI: 10.1111/bjh.14866

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.PMID 28771673Read ↗

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression.Semantic proximity Read ↗

Pomalidomide enhances CAR-T cell therapeutic efficacy and Remodels Immune Microenvironment in Lymphoid MalignanciesSemantic proximity Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

Lenalidomide triggers T-cell effector functions in vivo in patients with follicular lymphomaSemantic proximity Read ↗

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaSemantic proximity Read ↗

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5qSemantic proximity Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

One-Year Follow-Up of Natural Killer Cell Activity in Multiple Myeloma Patients Treated With Adjuvant Lenalidomide Therapy.Semantic proximity Read ↗

Lenalidomide enhances CD19 CAR-T cell fitness and target-cell engagement in relapsed/refractory CLLSemantic proximity Read ↗

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial.Semantic proximity Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.